None listed
Conditions
Interventions
Drug : 1)Blad-care group: One session of transurethral intravesical instillation immediately after completion of surgery.
2)Oral medication group: Silodosin 8 mg plus trospium chloride 20 mg once dail
Sponsors
Kyungpook National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants must meet all of the following inclusion criteria to be eligible for this clinical study: Adults aged 19 to 80 years who are scheduled to undergo transurethral stone surgery and ureteral stent placement for renal or ureteral stones. Patients who are able to visit the outpatient clinic on the day of ureteral stent removal and within 2 weeks after stent removal. Patients who are able to complete the Korean version of the USSQ questionnaire by themselves. Patients who understand the purpose, procedures, risks, and benefits of the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: History of hypersensitivity or contraindication to silodosin, trospium chloride, or any component of Blad-care. Patients with neurogenic bladder or clinically significant risk of urinary retention. Use of medications from similar classes, including a-blockers, antimuscarinic agents, or ß3-agonists, within 14 days prior to enrollment. Patients requiring ureteral stenting for more than 2 weeks due to concomitant conditions such as ureteral stricture. Patients considered unsuitable for study participation or with safety concerns at the investigator’s discretion. Patients who refuse to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ureteral Stent-related symptoms and adverse effect | — |
Secondary
| Measure | Time frame |
|---|---|
| Ureteral Stent-related symptoms and adverse effect, approximately 2 weeks after stent removal | — |
Countries
Korea, Republic of
Contacts
Public ContactJun-Koo Kang
Kyungpook National University Hospital
Outcome results
None listed